Free Trial
NASDAQ:SLRN

Acelyrin (SLRN) Stock Price, News & Analysis

Acelyrin logo
$4.47 +0.04 (+0.90%)
(As of 12:00 PM ET)

About Acelyrin Stock (NASDAQ:SLRN)

Key Stats

Today's Range
$4.26
$4.50
50-Day Range
$4.31
$6.48
52-Week Range
$3.36
$8.89
Volume
120,175 shs
Average Volume
1.02 million shs
Market Capitalization
$448.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Moderate Buy

Company Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Acelyrin Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
68th Percentile Overall Score

SLRN MarketRank™: 

Acelyrin scored higher than 68% of companies evaluated by MarketBeat, and ranked 350th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Acelyrin has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Acelyrin has only been the subject of 2 research reports in the past 90 days.

  • Read more about Acelyrin's stock forecast and price target.
  • Earnings Growth

    Earnings for Acelyrin are expected to grow in the coming year, from ($2.57) to ($2.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acelyrin is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acelyrin is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acelyrin has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.33% of the float of Acelyrin has been sold short.
  • Short Interest Ratio / Days to Cover

    Acelyrin has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Acelyrin has recently decreased by 8.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Acelyrin does not currently pay a dividend.

  • Dividend Growth

    Acelyrin does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.33% of the float of Acelyrin has been sold short.
  • Short Interest Ratio / Days to Cover

    Acelyrin has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Acelyrin has recently decreased by 8.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Acelyrin has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Acelyrin this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    4 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Acelyrin insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acelyrin's insider trading history.
Receive SLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter.

SLRN Stock News Headlines

Man behind OpenAI makes shocking new bet
Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.
HC Wainwright Increases Earnings Estimates for Acelyrin
Acelyrin’s Phase 3 Trial Progress and Uncertainties Lead to Hold Rating
See More Headlines

SLRN Stock Analysis - Frequently Asked Questions

Acelyrin's stock was trading at $7.46 at the beginning of the year. Since then, SLRN stock has decreased by 39.9% and is now trading at $4.48.
View the best growth stocks for 2024 here
.

Acelyrin, Inc. (NASDAQ:SLRN) posted its earnings results on Tuesday, August, 13th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.08.

Acelyrin (SLRN) raised $540 million in an IPO on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share.

Top institutional investors of Acelyrin include Geode Capital Management LLC (1.65%), Jacobs Levy Equity Management Inc. (1.33%), State Street Corp (1.28%) and Ikarian Capital LLC (0.68%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg, Daniel J Becker and Ronald Oyston.
View institutional ownership trends
.

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acelyrin investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Netflix (NFLX).

Company Calendar

Last Earnings
8/13/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLRN
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.50
High Stock Price Target
$20.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+159.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-381,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.74 per share

Miscellaneous

Free Float
86,682,000
Market Cap
$444.46 million
Optionable
Optionable
Beta
1.98
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:SLRN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners